Compare · AMGN vs BCDA
AMGN vs BCDA
Side-by-side comparison of Amgen Inc. (AMGN) and BioCardia Inc. (BCDA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and BCDA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $186.59B, about 17830.7x BCDA ($10.5M).
- Over the past year, AMGN is up 19.1% and BCDA is down 58.3% - AMGN leads by 77.5 points.
- AMGN has been more active in the news (19 items in the past 4 weeks vs 11 for BCDA).
- AMGN has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- Amgen Inc.
- BioCardia Inc.
- Price
- $345.61-1.12%
- $0.95-8.65%
- Market cap
- $186.59B
- $10.5M
- 1M return
- +5.03%
- -13.64%
- 1Y return
- +19.15%
- -58.33%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- News (4w)
- 19
- 11
- Recent ratings
- 25
- 1
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest BCDA
- BioCardia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioCardia Announces $4.4 Million Financing
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
- President and CEO Altman Peter bought $1,570 worth of shares (1,700 units at $0.92), increasing direct ownership by 0.58% to 293,266 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency
- BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase